Skip to main content

Table 1 Demographic and clinicopathologic characteristics in the development cohort

From: Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations

VariableValue
Sex, n (%)
 Male132 (46.6)
 Female151 (53.4)
Age, median (range)65.4 y (27.5–90.2 y)
Race/ethnicity, n (%)
 Caucasian215 (76.0)
 Asian27 (9.5)
 Black19 (6.7)
 Hispanic21 (7.4)
 Unknown1 (0.3)
Smoking status, n (%)
 Never-smoker64 (22.6)
 Former smoker136 (48.1)
 Current smoker82 (29.0)
 Unknown1 (0.3)
Vital status, n (%)
 Alive172 (60.8)
 Deceased111 (39.2)
Molecular platform, n (%)
 NGS218 (77.0)
 PCRa55 (19.5)
 Not done10 (3.5)
Molecular subtype, n (%) (n = 233)
 sTRU – EGFR (%)34 (14.6)
 sPP – KRAS (%)43 (18.5)
 sPI – TP53 (%)46 (19.7)
 Co-mutation60 (25.8)
EGFR/TP5326 (11.2)
KRAS/ TP5334 (14.6)
 Non-TRUPPPI21 (9.0)
 No mutations detected by NGS29 (12.4)
FISH results, n (%)
 Negative250 (88.3)
 Positive24 (8.5)
ALK16 (5.7)
ROS11 (0.4)
RET2 (0.7)
MET5 (1.8)
 Indeterminate9 (3.2)
 Aneuploidy193 (68.2)
  1. NGS Next-generation sequencing, PCR Polymerase chain reaction, sTRU Simplified terminal respiratory unit, sPP Simplified proximal-proliferative, sPI Simplified proximal-inflammatory, non-TRUPPPI Mutations in genes other than EGFR, KRAS, and TP53, FISH Fluorescence in situ hybridization
  2. aSanger sequencing or pyrosequencing